Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

VNRX

VolitionRX Ltd

May 28 • 04:00PM ET

2.88

-0.06 -2.04 %

Healthcare • Medical Devices • USA • Nano • AMEX

May 27, 8:20 AMVolitionRx issues corporate update, expects $5 million feline study milestone and Nu.Q NETs assay inclusion in France's government-backed DETECSEPS sepsis program

Peers: CTSO MODD NMTC NSPR NSYS TELA ECOR ELUT LUNG MOBI

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.21	Insider Own	16.76%	Shs Outstand	7.93M	Perf Week	15.66%
Market Cap	23.99M	Forward P/E	-	EPS next Y	-1.50	Insider Trans	0.00%	Shs Float	6.93M	Perf Month	3.60%
Enterprise Value	31.20M	PEG	-	EPS next Q	-0.65	Inst Own	13.43%	Short Float	6.06%	Perf Quarter	-38.72%
Income	-24.60M	P/S	9.71	EPS this Y	45.32%	Inst Trans	-	Short Ratio	0.66	Perf Half Y	-56.63%
Sales	2.47M	P/B	-	EPS next Y	37.45%	ROA	-280.22%	Short Interest	0.42M	Perf YTD	-43.66%
Book/sh	-4.03	P/C	7.74	EPS next 5Y	40.01%	ROE	-	52W High	18.80 -84.68%	Perf Year	-70.71%
Cash/sh	0.37	P/FCF	-	EPS past 3/5Y	26.33% 13.42%	ROIC	-	52W Low	1.91 51.10%	Perf 3Y	-90.07%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	77.98% 164.15%	Gross Margin	51.88%	Volatility	12.52% 12.02%	Perf 5Y	-95.87%
Dividend TTM	-	EV/Sales	12.63	EPS Y/Y TTM	21.17%	Oper. Margin	-874.51%	ATR (14)	0.31	Perf 10Y	-95.65%
Dividend Ex-Date	-	Quick Ratio	0.33	Sales Y/Y TTM	88.49%	Profit Margin	-997.46%	RSI (14)	53.73	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	0.33	EPS Q/Q	13.81%	SMA20	16.20%	Beta	1.07	Target Price	20.21
Payout	-	Debt/Eq	-	Sales Q/Q	299.81%	SMA50	-6.16%	Rel Volume	0.43	Prev Close	2.94
Employees	75	LT Debt/Eq	-	Earnings	May 14 AMC	SMA200	-57.12%	Avg Volume	638.59K	Price	2.88
IPO	Apr 25, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	-32.88% -35.16%	Trades		Volume	271,620	Change	-2.04%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-25	Initiated	H.C. Wainwright	Buy	$2.50
Feb-01-23	Downgrade	The Benchmark Company	Buy → Hold
Feb-17-22	Resumed	Cantor Fitzgerald	Overweight	$8 → $7
Mar-10-21	Initiated	Cantor Fitzgerald	Overweight	$8
May-16-18	Initiated	Maxim Group	Buy	$6
May-14-18	Reiterated	The Benchmark Company	Buy	$7 → $5
Sep-07-16	Reiterated	Rodman & Renshaw	Buy	$12 → $10
Feb-01-16	Initiated	Rodman & Renshaw	Buy	$12

May-27-26 08:17AM	VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets (PR Newswire)
May-15-26 07:02PM	VolitionRX Ltd (VNRX) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com) -9.09% +14.00%
May-14-26 06:32PM	VolitionRX: Q1 Earnings Snapshot (Associated Press) -6.78%
04:10PM	VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update (PR Newswire)
May-11-26 08:19AM	VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update (PR Newswire) -8.89%
08:17AM	Loading…
May-06-26 08:17AM	VolitionRx Announces Submission of Manuscript for Nu.Q Vet Cancer Test in Cats (PR Newswire) +6.87%
Apr-29-26 08:17AM	Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing (PR Newswire) -5.04%
Apr-23-26 08:12AM	VolitionRx Announces Acceptance of Compliance Plan by NYSE American (PR Newswire) -8.69%
Apr-20-26 07:30AM	Volition Launches rNuQ Webshop Broadening Product Range (PR Newswire) -8.72%
Apr-02-26 09:01PM	VolitionRX Ltd (VNRX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com) -14.25%
Apr-01-26 08:30AM	VolitionRx Limited Q4 2025 Earnings Call Summary (Moby)
Mar-31-26 06:51PM	VolitionRX: Q4 Earnings Snapshot (Associated Press) +6.32%
04:05PM	VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update (PR Newswire)
09:18AM	VolitionRX Ltd (VNRX) Q4 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
08:16AM	VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium (PR Newswire)
08:13AM	Loading…
Mar-30-26 08:13AM	Volition Announces Mayo Clinic Study Demonstrates Nu.Q Concentrations are Elevated in Trauma Patients (PR Newswire)
Mar-26-26 08:17AM	Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference (PR Newswire)
Mar-25-26 04:12PM	VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update (PR Newswire)
08:17AM	Volition Announces Detection of Over 95% of Early-Stage Cancers (PR Newswire)
Mar-18-26 08:17AM	Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA (PR Newswire) +5.26%
Mar-07-26 08:18AM	VolitionRx announces automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems (TipRanks)
Mar-06-26 08:10AM	Volition Announces First Ever Automated Nu.Q Vet Cancer Test with Fujifilm Vet Systems (PR Newswire)
Feb-25-26 08:10AM	VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution (PR Newswire) +25.62%
Feb-10-26 08:07AM	Volition Announces the Appointment of New Distributor for Nu.Q Discover (PR Newswire)
Feb-09-26 05:20PM	VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards (PR Newswire)
Feb-04-26 08:45AM	Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation (PR Newswire)
Jan-30-26 08:50AM	VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q Cancer Assays (PR Newswire) +13.50%
Jan-27-26 08:00AM	Volition Announces Data to Support Use of Nu.Q NETs in New Indication (PR Newswire)
Jan-20-26 08:25AM	Volition Continues to Extend Access to Nu.Q Vet Cancer Test (PR Newswire) +8.42%
Jan-16-26 08:45AM	Volition Sponsors Symposium at Veterinary Meeting and Expo (PR Newswire)
09:15AM	Loading…
Jan-08-26 09:15AM	VolitionRx Secures $2.0 Million in Funding (PR Newswire) +24.19%
08:45AM	VolitionRx Announces Breakthrough Clinical Data for Nu.Q Vet Cancer Test in Cats (PR Newswire)
Dec-17-25 08:45AM	Volition Issues Business Review 2025 (PR Newswire) +10.33%
Dec-11-25 09:00AM	Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment (PR Newswire)
Dec-08-25 09:00AM	Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer (PR Newswire)
Dec-04-25 09:00AM	VolitionRx Limited Announces Inclusion of its Nu.Q NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis (PR Newswire) +9.49%
Nov-25-25 08:45AM	VolitionRx Limited Announces the First Sale of the Nu.Q Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use (PR Newswire) -9.97%
Nov-14-25 04:01PM	VolitionRX Ltd (VNRX) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Revenue ... (GuruFocus.com) -6.60%
Nov-13-25 05:41PM	VolitionRX: Q3 Earnings Snapshot (Associated Press Finance)
04:10PM	VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update (PR Newswire)
07:30AM	VolitionRX Ltd (VNRX) Q3 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Nov-10-25 08:45AM	VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update (PR Newswire)
Oct-17-25 08:00AM	Volition Donates Nu.Q Vet Cancer Tests to HOPE Animal-Assisted Crisis Response Dogs (PR Newswire)
Oct-10-25 08:30AM	VolitionRx Limited Announces Pricing of $6.0 Million Underwritten Public Offering of Common Stock and Common Stock Warrants (PR Newswire) -22.65%
Oct-09-25 04:05PM	VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock and Common Stock Warrants (PR Newswire) -7.41%
Oct-02-25 08:45AM	Volition Sponsors Upcoming GenomeWeb Webinar (PR Newswire)
Sep-29-25 09:30AM	Volition Signs Co-Marketing and Services Agreement with Hologic (PR Newswire)
Sep-09-25 08:45AM	Volition Signs First Human Out Licensing Deal (PR Newswire)
Aug-16-25 03:03AM	VolitionRX Ltd (VNRX) Q2 2025 Earnings Call Highlights: Revenue Growth and Strategic Advances ... (GuruFocus.com)
Aug-14-25 05:06PM	VolitionRX: Q2 Earnings Snapshot (Associated Press Finance) +7.94%
04:10PM	VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update (PR Newswire)
09:28AM	VolitionRX Ltd (VNRX) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-08-25 08:30AM	VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update (PR Newswire)
Aug-04-25 04:01PM	VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering (PR Newswire)
Jul-16-25 08:00AM	Nu.Q Discover Expands Global Adoption and Epigenetic Innovation (PR Newswire) +8.36%
Jul-08-25 08:00AM	Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes (PR Newswire)
Jun-12-25 08:30AM	Volition Announces MARS Consortium Clinical Study Suggests Nu.Q H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure (PR Newswire) +5.97%
Jun-04-25 09:00PM	Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties (PR Newswire) +5.85%
May-19-25 08:30AM	VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats (PR Newswire)
May-17-25 03:02AM	VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones (GuruFocus.com)
May-15-25 06:12PM	VolitionRX: Q1 Earnings Snapshot (Associated Press Finance) -5.22%
05:37PM	VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update (PR Newswire)
09:22AM	VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-12-25 08:30AM	VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update (PR Newswire)
May-07-25 08:30AM	VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q NETs test adoption (PR Newswire)
Apr-29-25 08:30AM	VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets (PR Newswire) +9.27%
Apr-01-25 03:03AM	VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances (GuruFocus.com) -9.03%
12:31AM	VolitionRx Limited (VNRX) Q4 2024 Earnings Call Transcript (Seeking Alpha)
Mar-31-25 04:05PM	VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update (PR Newswire)
Mar-28-25 08:00AM	Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025 (PR Newswire)
Mar-27-25 08:30AM	Volition to Host Virtual Investor Event on Nu.Q Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 (PR Newswire)
Mar-26-25 08:00AM	VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering (PR Newswire) -6.87%
Mar-25-25 09:30AM	VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update (PR Newswire)
Mar-21-25 08:30AM	Volition's Nu.Q Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry (PR Newswire)
Mar-20-25 08:30AM	Volition Introduces Nu.Q Cancer Blood Test in New Industry Primer for Lung Cancer (PR Newswire)
Mar-17-25 08:30AM	Volition Proudly Sponsors the 44th ISICEM Congress (PR Newswire)
Mar-13-25 08:30AM	Volition Signs first ever Nu.Q Vet Cancer Test Automation Agreement with Fujifilm Vet Systems (PR Newswire)
Mar-11-25 08:30AM	Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q Lung Cancer Test (PR Newswire)
Mar-04-25 08:30AM	Volition's Nu.Q Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time (PR Newswire)
Feb-28-25 08:30AM	Volition Showcases Nu.Q Vet Cancer Test at the 97th WVC Annual Conference (PR Newswire)
Feb-06-25 08:30AM	Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis (PR Newswire) +6.08%
Feb-05-25 09:15AM	Volition to Host Virtual Investor Event on Nu.Q NETs, "Casting a New Light on Sepsis Management", on February 14, 2025 (PR Newswire)
Jan-30-25 08:30AM	Large clinical study establishes Nu.Q NETs H3.1 as an independent predictor of 28-day mortality in sepsis (PR Newswire)
Jan-08-25 08:30AM	Volition Issues Business Review 2024 (PR Newswire)
Dec-12-24 08:00AM	VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants (PR Newswire) -6.30%
Dec-10-24 08:00AM	Study shows Nu.Q Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening (PR Newswire)
Dec-06-24 09:00AM	VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering (PR Newswire) +9.93%
Nov-16-24 02:02AM	VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Nov-15-24 05:32AM	VolitionRX: Q3 Earnings Snapshot (Associated Press Finance) -5.56%
Nov-14-24 04:10PM	VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update (PR Newswire) -5.76%
07:19AM	VolitionRX Ltd (VNRX) Q3 2024 Earnings Report Preview: What to Look For (GuruFocus.com)
Nov-08-24 08:00AM	VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update (PR Newswire) +5.44%
Nov-06-24 04:10PM	Volition Appoints Timothy I. Still as Chairman (PR Newswire) +9.29%
Oct-31-24 08:00AM	Multiple studies show Nu.Q NETs test could predict sepsis patients at risk of deteriorating (PR Newswire) -9.39%
Oct-09-24 08:00AM	Volition to share new 'NETs in sepsis management' data insights at upcoming webinar (PR Newswire) -9.42%
Oct-03-24 08:00AM	Volition hosts NETs in sepsis management symposium at ESICM Lives 2024 (PR Newswire) +9.32%
Sep-30-24 04:10PM	Volition Appoints Dr. Ethel Rubin as an Independent Director (PR Newswire) +5.82%
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
Sep-11-24 08:00AM	Volition Hosts KOL Roundtable on Sepsis (PR Newswire) +7.21%

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

FounderMr. Cameron Reynolds MBA

Chief Operating OfficerDr. Gaetan Michel Ph.D.

CFO & TreasurerMr. Terig Hughes

Ph.D.Dr. Jacob Vincent Micallef MBA

Group General CounselMr. Nicholas Plummer

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Reynolds Cameron John	President and CEO	Nov 17 '25	Buy	0.35	20,000	7,000	2,554,847	Nov 17 01:12 PM
Reynolds Cameron John	President and CEO	Oct 14 '25	Buy	0.51	110,000	56,100	2,534,847	Oct 15 04:05 PM
Innes Guy Archibald	Director	Oct 14 '25	Buy	0.51	96,153	49,038	1,062,967	Oct 15 04:05 PM
STILL TIMOTHY I	Director	Oct 14 '25	Buy	0.51	48,076	24,519	1,535,458	Oct 15 04:05 PM
Reynolds Cameron John	President and CEO	Sep 12 '25	Buy	0.66	15,000	9,885	2,624,847	Sep 15 09:00 AM
Innes Guy Archibald	Director	Aug 05 '25	Buy	0.64	78,125	50,000	966,814	Aug 06 09:00 AM
Reynolds Cameron John	President and CEO	Aug 05 '25	Buy	0.64	78,125	50,000	2,609,847	Aug 06 09:00 AM
Reynolds Cameron John	President and CEO	Jun 12 '25	Buy	0.59	12,500	7,372	2,331,722	Jun 16 08:27 AM
Innes Guy Archibald	Director	Jun 03 '25	Buy	0.54	20,000	10,772	888,689	Jun 04 07:55 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VNRX

VolitionRX Ltd

Upgrade your Finviz experience